View Older Stories View More Recent Stories

Jul 25, 2018 06:45AM REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patient
Jul 25, 2018 05:58AM Merck (MRK) Reports Phase 3 KEYNOTE-048 Trial Investigating KEYTRUDA (pembrolizumab) Anti-PD-1 Therapy Met Primary Endpoint of OS
Jul 25, 2018 12:00AM KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose
Jul 24, 2018 12:15PM Merck Announces Fourth-Quarter 2018 Dividend
Jul 24, 2018 06:51AM Merck (MRK) Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Jul 24, 2018 06:45AM Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Jul 19, 2018 02:50PM Merck (MRK) Won't Increase Average Price of Portfolio by More than Inflation, Lowers Some Drug Prices
Jul 19, 2018 02:47PM Merck Reinforces Commitment to Responsible Pricing
Jul 12, 2018 08:13AM Pfenex (PFNX) Secures Milestone Payment from Merck (MRK) for Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
Jul 11, 2018 06:46AM Merck (MRK) Announces FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Patients with Advanced Hepatocellular Carcinoma
Jul 11, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Hepatocellular Carcinoma
Jul 2, 2018 06:48AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Chemotherapy as First-Line Treatment for Metastatic NSCLC
Jul 2, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy as First-Line Treatment for Metastatic Squamous Non-S
Jul 2, 2018 06:30AM Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018
Jul 2, 2018 05:46AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Approval for LYNPARZA (olaparib) in Japan for BRCA-Mutated Metastatic Breast Cancer
Jul 2, 2018 02:00AM LYNPARZA® (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer
Jun 27, 2018 05:01PM Merck (MRK) Announces Findings from WHO-led Study of Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
Jun 27, 2018 05:00PM Merck Announces Findings from WHO-led Study of Investigational Heat-Stable Carbetocin for Preventing Excessive Bleeding After Childbirth
Jun 27, 2018 07:11AM UPDATE: Merck (MRK), AstraZeneca (AZN) Report Positive Results from Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 27, 2018 07:00AM REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 27, 2018 06:45AM Merck to Hold Second-Quarter 2018 Sales and Earnings Conference Call on July 27
Jun 27, 2018 02:00AM LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Jun 25, 2018 06:31AM Merck (MRK) Says FDA Accepted sBLA for its KEYTRUDA as Adjuvant Therapy in Advanced Melanoma
Jun 25, 2018 06:30AM FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma
Jun 25, 2018 06:00AM Merck (MRK) Announces New Data from Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA (sitagliptin)
Jun 23, 2018 10:00AM Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)
Jun 13, 2018 04:07PM Merck (MRK) Announces FDA Approval of its KEYTRUDA for Treatment of Refractory or Relapsed PMBCL
Jun 13, 2018 04:06PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Jun 13, 2018 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for GARDASIL9 in Women and Men Ages 27 to 45 for Prevention of Certain HPV-Related Cancers and Diseases
Jun 13, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases
Jun 12, 2018 04:07PM Merck (MRK) Announces FDA Approval of its KEYTRUDA for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer
Jun 12, 2018 04:06PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
Jun 4, 2018 05:03PM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA in Combination with Abiraterone Delayed Disease Progression in mCRPC
Jun 4, 2018 05:00PM LYNPARZA® (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer
Jun 4, 2018 08:00AM Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Jun 4, 2018 07:46AM Merck (MRK) Says KEYTRUDA Showed Promising Anti-Tumor Activity in Patients with Advanced SCLC in Phase 2 KEYNOTE-158 Study
Jun 4, 2018 07:45AM Merck’s KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study
Jun 4, 2018 07:36AM Merck (MRK) Highlights Long-Term Survival Benefit in KEYTRUDA® (pembrolizumab)
Jun 4, 2018 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma
Jun 4, 2018 06:22AM Merck (MRK) & Eisai Highlights New Data and Analyses of LENVIMA (lenvatinib) in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab)
Jun 4, 2018 06:17AM Merck's (MRK) KEYTRUDA Plus Chemo Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous NSCLC
Jun 3, 2018 06:00PM Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
Jun 3, 2018 09:00AM Merck’s KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Stud
Jun 3, 2018 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study
Jun 3, 2018 07:30AM KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-
Jun 1, 2018 08:06AM Advaxis (ADXS) Announced Prelim. Data from Ongoing Metastatic, Castration Resistant Prostate Cancer (mCRPC) Phase 1/2 KEYNOTE-046 Study, Conducted in Conjunction with Merck (MRK) Evaluating ADXS-PSA
May 31, 2018 08:53AM Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection
May 24, 2018 07:34PM Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
May 24, 2018 07:05AM Foundation Medicine (FMI) Reports Immuno-Oncology Companion Diagnostics Collaboration with Merck (MRK)
May 23, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved OS and PFS as First-Line Treatment for NSCLC in Pivotal Phase 3 KEYNOTE-407 Trial
View More Recent Stories View Older Stories